Development of a Model to Predict 10-Year Risk of Ischemic and Hemorrhagic Stroke and Ischemic Heart Disease Using the China Kadoorie Biobank

Songchun Yang, PhD candidate, Yuting Han, PhD candidate, Canqing Yu, PhD, Yu Guo, MSc, Yuanjie Pang, PhD, Dianjianting Sun, PhD, Pei Pei, MSc, Ling Yang, PhD, Yiping Chen, DPhil, Huaidong Du, PhD, Hao Wang, MSc, M. Sofia Massa, PhD, Derrick Bennett, PhD, Robert Clarke, FRCP, Junshi Chen, MD, Zhengming Chen, DPhil, Jun Lv, PhD, and Liming Li, MPH, on behalf of the China Kadoorie Biobank Collaborative Group

Abstract

Background and Objectives

Contemporary cardiovascular disease (CVD) risk prediction models are rarely applied in routine clinical practice in China due to substantial regional differences in absolute risks of major CVD types within China. Moreover, the inclusion of blood lipids in most risk prediction models also limits their use in the Chinese population. We developed 10-year CVD risk prediction models excluding blood lipids that may be applicable to diverse regions of China.

Methods

We derived sex-specific models separately for ischemic heart disease (IHD), ischemic stroke (IS), and hemorrhagic stroke (HS) in addition to total CVD in the China Kadoorie Biobank. Participants were age 30–79 years without CVD at baseline. Predictors included age, systolic and diastolic blood pressure, use of blood pressure–lowering treatment, current daily smoking, diabetes, and waist circumference. Total CVD risks were combined in terms of conditional probability using the predicted risks of 3 submodels. Risk models were recalibrated in each region by 2 methods (practical and ideal) and risk prediction was estimated before and after recalibration.

Results

Model derivation involved 489,596 individuals, including 45,947 IHD, 43,647 IS, and 11,168 HS cases during 11 years of follow-up. In women, the Harrell C was 0.732 (95% CI 0.706–0.758), 0.759 (0.738–0.779), and 0.803 (0.778–0.827) for IHD, IS, and HS, respectively. The Harrell C for total CVD was 0.734 (0.732–0.736), 0.754 (0.752–0.756), and 0.774 (0.772–0.776) for models before recalibration, after practical recalibration, and after ideal recalibration. The calibration performances improved after recalibration, with models after ideal recalibration showing the best model performances. The results for men were comparable to those for women.

Discussion

Our CVD risk prediction models yielded good discrimination of IHD and stroke subtypes in addition to total CVD without including blood lipids. Flexible recalibration of our models for different regions could enable more widespread use using resident health records covering the overall Chinese population.
Glossary

CKB = China Kadoorie Biobank; CVD = cardiovascular diseases; DBP = diastolic blood pressure; HR = hazard ratio; HS = hemorrhagic stroke; ICD-10 = International Classification of Diseases, Tenth Revision; ICH = intracerebral hemorrhage; IDI = integrated discrimination improvement; IHD = ischemic heart disease; IS = ischemic stroke; NBPHSP = National Basic Public Health Service Program; RHR = resident health record; SAH = subarachnoid hemorrhage; SBP = systolic blood pressure; WC = waist circumference.

Classification of Evidence

This study provides Class I evidence that a prediction model incorporating accessible clinical variables predicts 10-year risk of IHD, IS, and HS in the Chinese population age 30–79 years.

Cardiovascular diseases (CVD), including ischemic heart disease (IHD), ischemic stroke (IS), and hemorrhagic stroke (HS), are the leading causes of the global burden of diseases.1 Risk prediction models are important tools for identifying high-risk individuals for early interventions in the primary prevention of CVD. Although the availability of many models has prompted researchers to focus on tailoring and improving existing models in local populations,2 there is currently no model that simultaneously has the following characteristics and can be widely used in the Chinese population.

The first is to distinguish the risks between IS and HS. The Chinese population has a much higher incidence of HS than Western populations.3 However, currently recommended models worldwide, including China, either did not include HS as the outcome4,5 or did not distinguish IS from HS.5-9

The second is to achieve efficient and widespread use of the risk prediction model by linking to dynamic electronic health records.3,6,10-12 In China, establishing resident health records (RHRs) has been one of the basic services provided by the National Basic Public Health Service Program (NBPHSP) since 2009, covering the whole population in the Chinese mainland. The free RHRs for the whole population include sociodemographic information, personal and family medical history, lifestyle, and noninvasive physical examinations (e.g., height, weight, waist circumference [WC], and blood pressure). Free blood cholesterol measurements are only provided to people ≥65 years of age. However, previous models mostly rely on blood lipids.3-7,9

The third is to be widely applicable to different regions. Risk factors for different CVD subcategories may vary or have different effect estimates.13-15 For a model that predicts the risk of composite outcome (single-model estimated, such as total CVD), the magnitude of association (i.e., regression coefficient in the model) might be affected by the composition proportion of each CVD subcategory in the derivation dataset, leading to potentially biased estimations. Therefore, considering that the absolute risks of 3 CVD subcategories vary substantially among different regions in China,16 previous risk prediction models based on single-model approach are less applicable to broad areas of China.3-7,9 To address this issue, the WHO CVD Risk Chart Working Group has proposed a new modeling and recalibration approach to help adapt the original models to different regions.6-8

Based on the China Kadoorie Biobank (CKB), one of the largest population-based cohorts globally, the present report primarily aimed to develop pragmatic disease-specific and overall CVD risk prediction models based on widely available variables in RHRs of China, covering IHD, IS, and HS. Next, we evaluated 2 model recalibration approaches based on the method proposed by the WHO CVD Risk Chart Working Group to adapt our models to different regions. We further evaluated the potential incremental value of more predictors to the derived models.

Methods

Study Population

CKB is an ongoing prospective study of 512,725 participants age 30 to 79 years who were enrolled from 5 urban and 5 rural regions situated in the northeast, northwest, east, south, and southwest of China during 2004–2008. The study regions were selected according to local disease patterns, exposure to risk factors, population stability, quality of death and disease registries, and local commitment and capacity. Within each study region, all potentially eligible participants in each of 100–150 rural villages or urban residential committees were invited to take part in the survey. The estimated population response rate was about 30% (26%–38% in the 5 rural regions and 16%–50% in the 5 urban regions). Details of the study have been described elsewhere.17 Briefly, all participants had valid baseline data, including a complete interviewer-administered laptop-based questionnaire and physical measurements conducted by trained health workers using calibrated instruments and standard protocols. A 10-mL random blood sample was collected for each participant with the time of the last meal recorded.

Study Design

In this study, 4 interrelated components were involved (Figure 1): (1) predictor selection—we selected several
predictors from a predefined list of candidate variables for model derivation; (2) model derivation—we then derived sex-specific and outcome-specific 10-year CVD risk prediction models among participants without CVD at baseline; namely, the CKB-CVD models; (3) demonstration of model recalibration—to support the flexible updating of the derived models, we compared 2 methods of recalibration; (4) evaluation of model updating—based on the derived models, we further evaluated the predictive utility of CVD risk factors that were not included in the model derivation process.

Assessment of Candidate Predictors
We predefined 16 candidate predictors (eTable 1, links.lww.com/WNL/B91S) for model derivation according to the following criteria: (1) established or probable risk factors of CVD; (2) widely available in RHRs; and (3) available in the CKB baseline survey. Other CVD risk factors that are not widely available in RHRs (eTable 1) were used to explore the ability to improve the derived models.

The baseline questionnaire collected information on sociodemographic characteristics, lifestyle behaviors, dietary habits, and personal and family medical history. All participants were asked “How often do you smoke tobacco now?”; the 4 response options were (1) do not smoke now, (2) only occasionally, (3) on most days, and (4) every day. Current daily smokers were defined as those who answered (4). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline were measured using a UA-779 digital sphygmomanometer. Measurements were made after a minimum of 5 minutes of sitting and repeated twice. If the 2 measurements for SBP were more than 10 mm Hg apart, a third measurement was taken. Only the last 2 readings were recorded and averaged for further analyses. Use of blood pressure–lowering treatment was self-reported by participants and was defined as answering “yes” to “Is your diagnosed hypertension still on treatment?” or “Did you take any drugs to lower blood pressure in the last 2 days?” History of diabetes was defined as self-reported diabetes diagnosed by a physician before the baseline survey. We did not use random blood glucose measurements as our previous study did because of its limited availability in China. WC was measured midway between the iliac crest and the lower rib margin at the end of normal expiration using a flexible plastic tape to the nearest 0.1 cm. The assessment and definition of other candidate predictors are shown in eTable 1 (links.lww.com/WNL/B91S).

Ascertainment of Outcomes
All participants were followed up for incident disease outcomes since their enrollment at baseline. Incident events were identified by using linkages with local disease and death registries and the national health insurance system and supplemented by active follow-up. The loss to follow-up was <1% prior to censoring on December 31, 2017. Trained staff
Table 1 Summary of Available CKB Data Used in the Model Derivation

| Baseline characteristics                  | Women       | Men        |
|-------------------------------------------|-------------|------------|
| Total participants                        | 289,464     | 200,132    |
| Rural area                                | 163,410     | 114,776    |
| Age, y                                    | 50.4        | 51.8       |
| Current daily smoker                      | 5,874       | 11,218     |
| Use of blood pressure–lowering treatment  | 34,062      | 20,388     |
| Systolic blood pressure, mm Hg            | 126.0 (114.0–141.0) | 129.5 (119.0–143.0) |
| Diastolic blood pressure, mm Hg           | 76.0 (69.0–83.0) | 78.5 (71.5–86.0) |
| Waist circumference, cm                   | 78.2 (72.0–84.9) | 81.3 (74.5–88.5) |
| Self-reported diabetes                    | 8,258       | 5,055      |
| Screen-detected diabetes                  | 7,933       | 5,169      |
| Cardiovascular outcomes                  |             |            |
| Total person-years observed               | 3,185,178   | 2,137,503  |
| Follow-up time, y                        | 11.2 (10.3–12.2) | 11.1 (10.1–12.1) |
| Participants with follow-up ≥10 years     | 241,127     | 156,488    |
| Incident events during the first 10 years/total follow-up period | | |
| Ischemic heart disease                    | 22,765/27,158 | 15,907/18,789 |
| Hemorrhagic stroke                        | 4,482/5,352 | 4,998/5,816 |
| Ischemic stroke                           | 19,752/24,210 | 16,398/19,437 |
| Unspecified stroke                        | 1,199/1,522 | 1,112/1,344 |
| Total cardiovascular disease              | 41,152/48,845 | 32,342/37,619 |

Abbreviation: CKB = China Kadoorie Biobank.
Data are n (%) or median (25–75th percentile) unless otherwise specified.
*a Person-years were calculated as the time from the baseline date to the first of the following: death, loss to follow-up, or the global censoring date (December 31, 2017).
bOnly the first event was included.
cThe number of unspecified stroke events as the first stroke events: 434 in women and 337 in men.
dTotal cardiovascular disease events included ischemic heart disease events (fatal or nonfatal I20–I25) and stroke events (fatal or nonfatal I60–I64).
Table 2 Adjusted Hazard Ratios for Predictors in the CKB-CVD Models

| Ischemic heart disease | Women | | Main effect | Age interaction | Men | | Main effect | Age interaction |
|------------------------|-------|---|-------------|---------------|-----|---|-------------|---------------|
| Age per 5 years | 1.40 (1.38–1.41) | — | 1.43 (1.41–1.45) | — | 1.02 (1.01–1.03) | 1.00 (0.99–1.00) | 1.05 (1.04–1.07) | 1.00 (1.00–1.01) |
| SBP per 10 mm Hg | 1.05 (1.04–1.07) | 0.99 (0.99–1.00) | 1.10 (1.07–1.12) | 0.97 (0.96–0.97) | 1.55 (1.49–1.61) | 0.95 (0.93–0.97) | 1.59 (1.52–1.67) | 0.97 (0.95–0.99) |
| DBP per 10 mm Hg | 1.17 (1.08–1.28) | 0.97 (0.93–1.00) | 1.22 (1.19–1.26) | 0.98 (0.97–1.00) | 1.59 (1.49–1.69) | 0.94 (0.92–0.97) | 1.82 (1.69–1.95) | 0.91 (0.88–0.94) |
| Use of blood pressure-lowering treatment | 1.16 (1.14–1.17) | 0.97 (0.96–0.98) | 1.13 (1.11–1.15) | 0.97 (0.96–0.98) | 0.900 | — | 0.929 | — |
| Baseline survival estimate at 10 years* | 0.900 | — | 0.929 | — |

| Hemorrhagic stroke | | | | | | | | |
|-------------------|---|---|---|---|---|---|---|---|
| Age per 5 years | 1.45 (1.43–1.46) | — | 1.52 (1.50–1.54) | — | 1.09 (1.08–1.10) | 0.98 (0.97–0.98) | 1.13 (1.12–1.15) | 0.98 (0.97–0.98) |
| SBP per 10 mm Hg | 1.11 (1.09–1.13) | 0.99 (0.99–1.00) | 1.15 (1.13–1.17) | 0.98 (0.98–0.99) | 1.54 (1.48–1.60) | 0.96 (0.94–0.97) | 1.59 (1.52–1.67) | 0.94 (0.93–0.96) |
| DBP per 10 mm Hg | 1.30 (1.18–1.42) | 0.93 (0.89–0.96) | 1.29 (1.24–1.33) | 0.97 (0.96–0.99) | 1.82 (1.71–1.94) | 0.90 (0.87–0.93) | 1.83 (1.71–1.97) | 0.94 (0.91–0.97) |
| Use of blood pressure-lowering treatment | 1.11 (1.09–1.12) | 0.98 (0.97–0.98) | 1.08 (1.06–1.10) | 0.99 (0.99–1.00) | 0.910 | — | 0.928 | — |
| Baseline survival estimate at 10 years* | 0.910 | — | 0.928 | — |

Abbreviations: CKB = China Kadoorie Biobank; CVD = cardiovascular diseases; DBP = diastolic blood pressure; SBP = systolic blood pressure.

* The Cox models were stratified by 10 regions. Baseline survival estimate at 10 years (S₀ₜ) was estimated by pooling the S₀ₜ across regions weighted by the number of events by 10 years.

To simulate the process of applying the CKB-CVD models in different regions, model recalibration was performed separately for 10 study regions. We calculated the ideal performance metrics assuming the availability of observed 10-year risks in each study region (ideal recalibration). However, in practice, the observed 10-year risks of the target population are difficult to obtain. The recalibration process could also use age-specific (5-year age groups) and sex-specific mean risk factor levels and annual incidence estimates of CVD in each study region (practical recalibration) (eMethods, links.lww.com/WNL/B915). A Model performance before and after recalibration was evaluated in the whole derivation dataset and each study region. We also evaluated model performance before and after recalibration in participants <65 and ≥65 years of age, with and without hypertension, and with and without diabetes.

We further explored whether the remaining predictors (eTable 1, links.lww.com/WNL/B915) could be used for...
updating CKB-CVD models in the future. We added each predictor individually and evaluated its relative IDI for each major CVD subtype, as we did in the predictor selection component outlined above.

This study adhered to the TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) statement for reporting. Analyses were done with Stata 15.0. Figures were produced using R 3.6.0.

Standard Protocol Approvals, Registrations, and Patient Consents
CKB had ethical approvals from the Ethical Review Committee of the Chinese Center for Disease Control and Prevention (Beijing, China) and the Oxford Tropical Research Ethics Committee, University of Oxford (UK). All participants provided a written informed consent form.

Data Availability
Cohort description and questionnaires are available online. Statistical code is available from the corresponding author (J.L.). Details on how to access China Kadoorie Biobank data and details of the data release schedule are available online.

Results
Overview of the Study Population
The study population included 302,522 women and 210,203 men age 30–79 years at the baseline survey. Participants who had been diagnosed with IHD (n = 15,472) or stroke (n = 7,657) before the baseline survey were excluded from the derivation dataset (Figure 1). No participant had missing data on the main predictors used in the model derivation. The remaining 489,596 participants had a median age of 52 years (25th–75th percentile 43–60) for women and 50 years (42–58) for men (Table 1). During a median of 11 years of follow-up, 86,464 (17.7%) participants had CVD events, including 45,947 IHD, 43,647 IS, and 11,168 HS events. The standardized 10-year risks of 3 CVD subcategories varied greatly across regions (eFigure 1, links.lww.com/WNL/B915).

The Newly Derived CKB-CVD Models
Seven predictors were used to derive the sex-specific CKB-CVD models separately for 3 CVD subcategories (Table 2). The adjusted hazard ratios (HRs) of predictors varied across different sexes and different CVD subcategories. For example, HRs of DBP (per 10 mm Hg) ranged from 1.05 (95% CI 1.04–1.07) for IHD in women to 1.33 (1.29–1.38) for HS in men; HRs of WC (per 10 cm) ranged from 0.92 (0.89–0.95) for HS in women to 1.16 (1.14–1.17) for IHD in women. Regression coefficients for each predictor are provided in eAppendix 1 (links.lww.com/WNL/B916). An example risk calculation is shown in eMethods. The assumption of independence among risks of 3 CVD subcategories was not violated (eFigure 2). The HS submodel had the best discrimination performance in internal validation (Figure 2). Calibration performances of the 3 submodels were poor in most study regions (eFigure 3). In sensitivity analysis, we derived models separately for ICH, whose beta coefficients were similar to those of the HS models (eTable 4).

As for the combined model before recalibration (original model in the following), Harrell C was 0.734 (95% CI...
0.732–0.736) for women and 0.743 (0.741–0.746) for men in the derivation dataset (Figure 3), ranging from 0.705 (0.701–0.710) for women in Harbin to 0.804 (0.795–0.813) for women in Suzhou (eFigure 4, links.lww.com/WNL/B915). Calibration was poor in the derivation dataset (Figure 3) and most study regions (eFigure 5). Recalibration of the CKB-CVD Models After practical recalibration, Harrell C increased to 0.754 (95% CI 0.752–0.756) for women and 0.764 (0.762–0.766) for men, and calibration improved for both sexes in the derivation dataset. Models after ideal recalibration showed the best model performances (Figure 3). Harrell C in each study region almost remained unchanged after practical recalibration and ideal recalibration (data not shown). Calibration performances improved in almost all study regions after ideal recalibration and in half of the study regions after practical recalibration. The number of urban regions with improved calibration performance after practical recalibration was greater than those in rural regions (eFigure 5, links.lww.com/WNL/B915). An example of practical recalibration is shown in eMethods. We also provide an interactive 10-year CVD risk calculator and a calculator of practical recalibration measures in eAppendix 1 (links.lww.com/WNL/B916).

Discrimination of the original model was lower in the patients who were older (≥65 years), had hypertension, or had diabetes, especially in older women (Harrell C 0.584, 95% CI 0.579–0.589) (eFigure 6, links.lww.com/WNL/B915). Separate recalibration in each study region improved the discrimination and the calibration among these participants (eFigures 7–9).
Evaluation of Model Updating
Based on the CKB-CVD models, only level of education and waist–hip ratio in men and total physical activity in women had relative IDI greater than 1% for the HS submodel. Other predictors had a small or no effect on improving the 3 submodels (Figure 4).

Classification of Evidence
This study provides Class I evidence that a prediction model incorporating accessible clinical variables predicts 10-year risk of IHD, IS, and HS in the Chinese population 30–79 years of age.

Discussion
In this large population-based Chinese cohort, we developed pragmatic sex-specific risk models that predict 10-year risks of CVD subcategories and overall CVD. Given the high burden of HS in the Chinese population, our models distinguish stroke subtypes and should be more applicable to the Chinese than previous models. Our models achieved good discrimination of risk groups, even without using blood lipids information, indicating a potentially wider use based on RHRs. Flexible model updating methods improved the model performance when used in different regions.

Two CVD primary prevention guidelines for Chinese individuals have recommended two 10-year CVD risk prediction models as risk assessment tools: one derived from the Chinese Multi-provincial Cohort Study (CMCS) and the other derived from the China-PAR Project.25,26 The loss to follow-up in both cohorts, 21.3%27 and 9.9%,7 respectively, may increase the risk of bias according to PROBAST.28 Also, both models relied on blood lipids, used hard IHD as the outcome, and did not consider the risk of HS separately.4,7 Few studies have derived risk prediction models for HS. One study was performed in a small cohort of 4,400 Chinese steelworkers recruited before 1980, with only 33 HS events in the derivation dataset.29 The other study was conducted using 3 population-based cohorts from the United States and the Netherlands and included 325 intracerebral hemorrhage (ICH) events.30 As for IHD, previous studies have reported that patients with angina also

Figure 4 Relative Integrated Discrimination Improvement of Other Predictors Based on the CKB-CVD Models

The relative integrated discrimination improvement (rIDI) (%) was calculated with the same method used in the predictor selection component (eMethods). Detailed categories of multicategorical variables are as follows: level of education (6 groups: no formal school, primary school, middle school, high school, technical school or college, and university); smoking status (5 groups: nonsmoker, former smoker, current smoker who smoked <10, 10–19, or ≥20 cigarettes or equivalents per day); alcohol consumption (7 groups: nondrinker, former drinker, weekly drinker, daily drinker with an intake of <15, 15–29, 30–59, or ≥60 g/d of pure alcohol); frequency of exercise (4 groups: never or rarely, 1–3 times/month, 1–5 times/week, and daily or almost daily); consumption frequency of fresh fruits, red meat, and eggs (5 groups: daily, 4–6 d/wk, 1–3 d/wk, monthly, and never or rarely). The total physical activity was natural log-transformed before analysis. Two participants had missing value of body mass index and were excluded from the current analysis. CKB = China Kadoorie Biobank; CVD = cardiovascular diseases; MET = metabolic equivalent; rIDI = relative integrated discrimination improvement.
have a poor prognosis. The simultaneous risk prediction of hard IHD and soft stroke might lead to misunderstandings among model users. Therefore, consistent with QRISK3 and PREDICT, we included such outcomes in high-risk population screening.

Most previous models only included SBP as the predictor. In the current study, the addition of DBP to the basic model for HS substantially improved the predictive ability. Although the relative IDI for the IHD and IS submodels was small, the category-free net reclassification improvement was >10% for IS and >5% for IHD in both sexes (data not shown). Body mass index was included as a predictor in the WHO non-laboratory-based model. However, it did not improve the predictive ability as much as WC in our analysis (the predictor selection component), consistent with the finding of the China-PAR Project. We therefore included DBP and WC as predictors, given their incremental values in outcome prediction and wide availability in RHRs of China. Our models used self-reported history of diabetes as a predictor, consistent with the practice of RHRs. Despite nearly half of the undiagnosed diabetes cases being excluded in our cohort, the addition of screen-detected diabetes only led to a minimal improvement of the 3 submodels.

Older individuals and individuals with hypertension or diabetes are major users of health services in China. We examined model performances stratified by these characteristics and found models had the lowest discrimination among individuals age ≥65 years. This is mostly due to the lower contribution of age to the models when the analysis was limited to older people. Previous models for older people, using traditional cardiovascular risk factors as predictors, also usually had Harrell C below 0.65. Because additional free blood tests are available for the elderly in the NBPHSP, there is a promise of improving risk prediction for the elderly by adding more predictors.

There were significant differences in the calibration performances of the original models across different study regions, including both the 3 submodels and the combined CVD risk model. This finding suggests that previous universal CVD risk prediction models may encounter the same problems when applied to different regions of China, highlighting the importance of model recalibration. The ideal recalibration is not easy to achieve because long-term follow-up is required to obtain the observed 10-year risks. The WHO CVD Risk Chart Working Group provided a flexible recalibration method based on cross-sectional population data (i.e., practical recalibration in our study). The current study suggests that the recalibration method proposed by WHO is effective. However, there was still a gap between practical recalibration and ideal recalibration. One possible explanation is that the number of participants in each 5-year age group was relatively small for each study region, leading to errors in estimating the mean risk factor levels and annual incidence of diseases. We assume that if a large and representative population was used to estimate the recalibration measures, the effect of practical recalibration would be closer to that of ideal recalibration. However, further studies are warranted.

This study population was uniquely large. The loss to follow-up was <1% prior to the global censoring date. More than 100,000 CVD events were documented during a follow-up of 11 years. Unspecified stroke accounted for only 1.4% and 1.2% of first stroke events in women and men. These advantages allowed us to derive risk prediction models separately for 3 CVD subcategories and obtain robust coefficient estimates. Our models have the potential to be widely used because of readily available predictors from the RHRs of China. The recalibration approach employed in this study enables the flexible updating of our models in different regions in China. We have provided a calculator of practical recalibration measures (eAppendix 1, links. lww.com/WNL/B916) and statistical codes required to calculate our models to support model updating.

Several limitations merit consideration. First, independent samples for external validation of our models are best from local populations in which our models are recalibrated to their CVD incidences and risk factor levels and evaluated the predictive performance. However, the lack of other regional cohorts of middle-aged and older adults with sufficiently large sample size and including >10 years of follow-up in China limits the options for an effective external validation. With the development of more regional cohorts launched by the China Precision Medicine Initiative and regional electronic RHRs system since the mid-2010s, further validation and updating of our models are warranted. Second, as a population-based cohort that aimed to follow up for a long time, CKB was not designed to be representative of the general population in China. Despite this, the inclusion of a considerable number of participants from different regions across China and with diverse sociodemographic characteristics enables the study to provide robust regression coefficients and be generalizable to broad populations. When the models are applied to other regions, a recalibration process based on local disease rates and risk factor levels helps improve the applicability of the models. Third, SAH accounts for only a small proportion of all HS cases in the Chinese population, with the corresponding proportion of <10% in CKB, precluding us from deriving robust models separately for SAH. We chose to present the HS models that did not distinguish between ICH and SAH in our primary analysis because the coefficients for ICH-specific models hardly ever changed.

Based on a large population-based cohort of Chinese adults, we developed 10-year risk prediction models for IHD, IS, HS, and their combined outcome that may be more widely applicable to RHRs in the NBPHSP of China. This study took account of the high burden of HS and substantial regional differences in absolute risks of major CVD types within China and derived models that can be adapted for different regions of the Chinese population.

**Acknowledgment**
The authors thank the study participants, the survey team members in each of the 10 regional centers, and the project development and management teams based at Beijing, Oxford, and the 10 regional centers.
Study Funding
This work was supported by the National Natural Science Foundation of China (82192904, 82192901, 82192900). The CKB baseline survey and the first re-survey were supported by a grant from the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up is supported by grants from the UK Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants from the National Key R&D Program of China (2016YFC0900500), National Natural Science Foundation of China (81390540), and Chinese Ministry of Science and Technology (2011BAI09B01). Derrick Bennett was supported by the National Institute of Health Research Biomedical Research Center Oxford. Zhengming Chen was supported by the UK Medical Research Council.

Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Publication History
Received by Neurology June 10, 2021. Accepted in final form January 18, 2022.

Appendix 1 Authors

| Name                  | Location                                                                 | Contribution                                                                                     |
|-----------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Songchun Yang, PhD    | Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China | Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data |
| Yuting Han, PhD       | Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China | Analysis or interpretation of data                                                                |
| Canqing Yu, PhD       | Department of Epidemiology & Biostatistics, School of Public Health, Peking University; Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing, China | Major role in the acquisition of data; Analysis or interpretation of data                           |
| Yu Guo, MSc           | Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, China         | Major role in the acquisition of data                                                              |
| Yuanjie Pang, PhD     | Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China | Analysis or interpretation of data                                                                |
| Dianjianyi Sun, PhD   | Department of Epidemiology & Biostatistics, School of Public Health, Peking University, Beijing, China | Analysis or interpretation of data                                                                |
| Pei Pei, MSc          | Chinese Academy of Medical Sciences, Beijing, China                        | Major role in the acquisition of data                                                                |

Appendix 1 (continued)

| Name                  | Location                                                                 | Contribution                                                                                     |
|-----------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Ling Yang, PhD        | Medical Research Council Population Health Research Unit at the University of Oxford; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK | Major role in the acquisition of data                                                               |
| Yiping Chen, DPhil    | Medical Research Council Population Health Research Unit at the University of Oxford; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK | Major role in the acquisition of data                                                               |
| Huaidong Du, PhD      | Medical Research Council Population Health Research Unit at the University of Oxford; Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK | Major role in the acquisition of data                                                               |
| Hao Wang, MSc         | NCDs Prevention and Control Department, Zhejiang CDC, Hangzhou, China     | Major role in the acquisition of data                                                               |
| M. Sofia Massa, PhD   | Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK | Drafting/revision of the manuscript for content, including medical writing for content               |
| Derrick Bennett, PhD  | Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK | Drafting/revision of the manuscript for content, including medical writing for content               |
| Robert Clarke, FRCP   | Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK | Drafting/revision of the manuscript for content, including medical writing for content               |
| Junshi Chen, MD       | China National Center for Food Safety Risk Assessment, Beijing, China     | Study concept or design                                                                            |
| Zhengming Chen, DPhil | Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, UK | Study concept or design                                                                            |
| Jun Lv, PhD           | Department of Epidemiology & Biostatistics, School of Public Health, Peking University; Peking University Center for Public Health and Epidemic Preparedness & Response; Key Laboratory of Molecular Cardiovascular Sciences, Peking University, Ministry of Education, Beijing, China | Drafting/revision of the manuscript for content, including medical writing for content; Study concept or design |
| Liming Li, MPH        | Department of Epidemiology & Biostatistics, School of Public Health, Peking University; Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing, China | Major role in the acquisition of data; Study concept or design; Other content                        |
References

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-1222.

2. Damen JA, Hoefl L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353:i2416.

3. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.

4. Wang M, Liu J, Zhao D. A new protocol for risk assessment of atherosclerotic cardiovascular disease in China. Chin J Cardiol. 2018;46:87-91.

5. Andrus B, Lacaille D. ACC/AHA guideline on the assessment of cardiovascular risk. Eur Heart J. 2021;42:2439-2454.

6. Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in the general population: systematic review. Eur J Prev Cardiol. 2015;22(3):380-388.

7. Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (prediction for ASCVD risk in China). Circulation. 2016;134(19):1430-1440.

8. The WHO CVDR Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7:e1332-e1345.

9. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439-2454.

10. Tu JV, Chu A, Donovan LR, et al. The Cardiovascular Health in Ambulatory Care Research Team (CANEART): using big data to measure and improve cardiovascular health and healthcare services. Circ Cardiovasc Qual Outcomes. 2015;8(2):204-212.

11. Hemingway H, Feder GS, Fitzpatrick NK, Denaxas S, Shah AD, Timmis AD. Hemingway H, Feder GS, Fitzpatrick NK, Denaxas S, Shah AD, Timmis AD. Separating the impact of blood pressure and other factors on cardiovascular disease: a systematic review. Ann Intern Med. 2019;170(1):W1-W33.

12. Zhang XF, Attia J, D’Este C, Yu XH, Wu XG. A risk score predicted coronary heart disease and stroke in a Chinese cohort. J Clin Epidemiol. 2005;58(9):951-958.

13. Perker BS, van Kempen BJ, Wieberdink RG, et al. Separate prediction of intracerebral hemorrhage and ischemic stroke. Neurology. 2014;82(20):1804-1812.

14. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006;295(12):1404-1411.

15. van Bussel EF, Hoevenaar-Blom MP, Poortvliet RKE, et al. Predictive value of traditional risk factors for cardiovascular disease in older people: a systematic review. Prev Med. 2020;132:105986.

16. Yang S. ckbcvdrisk: Program that calculates 10-year risks of cardiovascular disease and its three main subcategories using the “CKB-CVD models.” Accessed April 26, 2022. https://github.com/ckbiovac/cbk-cvd-risk.

17. Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol. 2011;40(6):1652-1666.

18. Bragg F, Holmes MV, Iona A, et al. Association between diabetes and cause-specific mortality in rural and urban areas of China. JAMA. 2017;317:280-289.

19. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.

20. D’Agostino RB, Nam BH. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Handbook of Statistics. Elsevier; 2003:1-25.

21. Pencina MJ, D’Agostino RB, Vasan RS Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172.

22. Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172.

23. Collins GS, Reitmo JA, Altman DG, Moons KG. Transparent reporting of a multi-variable prediction model for individual diagnosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55-63.

24. China Kadoorie Biobank Collaborative Group. China Kadoorie Biobank. Accessed April 26, 2022. https://www.ckbiovac.org/site/.

25. The Joint Task Force for the Guideline on the Assessment and Management of Cardiovascular Risk in China. Guideline on the assessment and management of cardiovascular risk in China. Chin J Prev Med. 2019;53:13-35.

26. Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association. Chinese guideline on the primary prevention of cardiovascular diseases. Chin J Cardiol. 2020;48:1000-1038.

27. Wang Y, Liu J, Wang W, et al. Lifetime risk for cardiovascular disease in a Chinese population: the Chinese Multi-Provincial Cohort Study. Eur J Prev Cardiol. 2015;22(3):380-388.

28. Moons KGM, Wolf RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1-W33.

29. Zhang XF, Attia J, D’Este C, Yu XH, Wu XG. A risk score predicted coronary heart disease and stroke in a Chinese cohort. J Clin Epidemiol. 2005;58(9):951-958.

30. Perker BS, van Kempen BJ, Wieberdink RG, et al. Separate prediction of intracerebral hemorrhage and ischemic stroke. Neurology. 2014;82(20):1804-1812.

31. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA. 2006;295(12):1404-1411.

32. van Bussel EF, Hoevenaar-Blom MP, Poortvliet RKE, et al. Predictive value of traditional risk factors for cardiovascular disease in older people: a systematic review. Prev Med. 2020;132:105986.

33. Yang S. ckbcvdrisk: Program that calculates 10-year risks of cardiovascular disease and its three main subcategories using the “CKB-CVD models.” Accessed April 26, 2022. https://github.com/ckbiovac/cbk-cvd-risk.

34. Wang Y, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults. Circulation. 2017;135(8):759-771.

35. Chen Y, Wang L, Chen N, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0.5 million Chinese adults. Lancet Glob Health. 2020;8:e580-e590.